Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.

ABSTRACT:

Background

Metastatic pancreatic ductal adenocarcinoma (mPDAC) bears a dismal prognosis due to the limited activity of systemic chemotherapy. In our platform for precision medicine, we aim to offer molecular-guided treatments to patients without further standard therapy options.

Methods

In this single center, real-world retrospective analysis of our platform, we describe the molecular-based therapy approaches used in all 50 patients diagnosed with therapy-refractory mPDAC. A molecular portrait of the tumor specimens was created by next-generation sequencing, immunohistochemistry (IHC), microsatellite instability (MSI) testing, and fluorescence in situ hybridization.

Results

In total, we detected 123 mutations in 50 patients. The five most frequent mutations wer

SUBMITTER: Taghizadeh H 

PROVIDER: S-EPMC7357054 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature